"Receptors, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere.
Descriptor ID |
D011971
|
MeSH Number(s) |
D12.776.543.750.705
|
Concept/Terms |
Receptors, Immunologic- Receptors, Immunologic
- Immunologic Receptors
- Immunological Receptors
- Receptors, Immunological
- Immunologic Receptor
- Receptor, Immunologic
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Immunologic".
- Receptors, Immunologic
- Costimulatory and Inhibitory T-Cell Receptors
- Immunophilins
- Integrins
- Leukocyte Immunoglobulin-like Receptor B1
- Lipopolysaccharide Receptors
- Platelet Membrane Glycoproteins
- Receptors, Antigen
- Receptors, Complement
- Receptors, Cytokine
- Receptors, Fc
- Receptors, Formyl Peptide
- Receptors, Laminin
- Receptors, Lymphocyte Homing
- Receptors, Mitogen
- Receptors, Natural Killer Cell
- Receptors, Pattern Recognition
- Receptors, Scavenger
- Signaling Lymphocytic Activation Molecule Family
- Triggering Receptor Expressed on Myeloid Cells-1
This graph shows the total number of publications written about "Receptors, Immunologic" by people in this website by year, and whether "Receptors, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 3 | 3 |
1995 | 1 | 0 | 1 |
1997 | 1 | 0 | 1 |
1999 | 2 | 1 | 3 |
2000 | 2 | 1 | 3 |
2001 | 2 | 0 | 2 |
2002 | 4 | 1 | 5 |
2003 | 5 | 2 | 7 |
2004 | 2 | 2 | 4 |
2005 | 5 | 3 | 8 |
2006 | 5 | 2 | 7 |
2007 | 9 | 2 | 11 |
2008 | 3 | 2 | 5 |
2009 | 3 | 1 | 4 |
2010 | 5 | 0 | 5 |
2011 | 4 | 2 | 6 |
2012 | 4 | 5 | 9 |
2013 | 3 | 2 | 5 |
2014 | 8 | 1 | 9 |
2015 | 4 | 0 | 4 |
2016 | 3 | 1 | 4 |
2017 | 3 | 4 | 7 |
2018 | 1 | 1 | 2 |
2019 | 4 | 0 | 4 |
2020 | 4 | 4 | 8 |
2021 | 3 | 3 | 6 |
2022 | 4 | 4 | 8 |
2023 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Immunologic" by people in Profiles.
-
LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy. Cancer Res. 2023 12 15; 83(24):4047-4062.
-
Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response. Sci Rep. 2023 06 18; 13(1):9865.
-
TMEM106B regulates microglial proliferation and survival in response to demyelination. Sci Adv. 2023 05 05; 9(18):eadd2676.
-
DDX58 Is Associated With Susceptibility to Severe Influenza Virus Infection in Children and Adolescents. J Infect Dis. 2022 11 28; 226(11):2030-2036.
-
Neuronal signal-regulatory protein alpha drives microglial phagocytosis by limiting microglial interaction with CD47 in the retina. Immunity. 2022 12 13; 55(12):2318-2335.e7.
-
TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer. 2022 09 26; 21(1):185.
-
Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer. J Nanobiotechnology. 2022 Sep 19; 20(1):417.
-
Novel dominant and recessive variants in human ROBO1 cause distinct neurodevelopmental defects through different mechanisms. Hum Mol Genet. 2022 08 23; 31(16):2751-2765.
-
Whole genome sequence association analysis of fasting glucose and fasting insulin levels in diverse cohorts from the NHLBI TOPMed program. Commun Biol. 2022 07 28; 5(1):756.
-
SIRPa Mediates IGF1 Receptor in Cardiomyopathy Induced by Chronic Kidney Disease. Circ Res. 2022 07 22; 131(3):207-221.